171 related articles for article (PubMed ID: 29335321)
1. Effectiveness and Cost of Weekly Recombinant Tissue Plasminogen Activator Hemodialysis Catheter Locking Solution.
Hemmelgarn BR; Manns BJ; Soroka SD; Levin A; MacRae J; Tennankore K; Wilson JS; Weaver RG; Ravani P; Quinn RR; Tonelli M; Kiaii M; Mossop P; Scott-Douglas N
Clin J Am Soc Nephrol; 2018 Mar; 13(3):429-435. PubMed ID: 29335321
[TBL] [Abstract][Full Text] [Related]
2. An economic evaluation of rt-PA locking solution in dialysis catheters.
Manns BJ; Scott-Douglas N; Tonelli M; Ravani P; LeBlanc M; Dorval M; Holden R; Moist L; Lok C; Zimmerman D; Au F; Hemmelgarn BR
J Am Soc Nephrol; 2014 Dec; 25(12):2887-95. PubMed ID: 25012176
[TBL] [Abstract][Full Text] [Related]
3. Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator.
Hemmelgarn BR; Moist LM; Lok CE; Tonelli M; Manns BJ; Holden RM; LeBlanc M; Faris P; Barre P; Zhang J; Scott-Douglas N;
N Engl J Med; 2011 Jan; 364(4):303-12. PubMed ID: 21268722
[TBL] [Abstract][Full Text] [Related]
4. Prevention of catheter lumen occlusion with rT-PA versus heparin (Pre-CLOT): study protocol of a randomized trial [ISRCTN35253449].
Hemmelgarn BR; Moist L; Pilkey RM; Lok C; Dorval M; Tam PY; Berall MJ; LeBlanc M; Toffelmire EB; Manns BJ; Scott-Douglas N;
BMC Nephrol; 2006 Apr; 7():8. PubMed ID: 16608513
[TBL] [Abstract][Full Text] [Related]
5. Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease.
Wang Y; Ivany JN; Perkovic V; Gallagher MP; Woodward M; Jardine MJ
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009631. PubMed ID: 27039404
[TBL] [Abstract][Full Text] [Related]
6. Concentration of heparin-locking solution and risk of central venous hemodialysis catheter malfunction.
Thomas CM; Zhang J; Lim TH; Scott-Douglas N; Hons RB; Hemmelgarn BR;
ASAIO J; 2007; 53(4):485-8. PubMed ID: 17667236
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intensive versus standard hemodialysis central venous catheter dysfunction protocol using rt-PA: a quality assurance initiative.
Wilson JA; Mossop P; Soroka SD; Dipchand C; Drost S; Sheehy N; Tennankore K
J Vasc Access; 2016; 17(2):143-50. PubMed ID: 26847735
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of citrate 4% and heparin as tunneled-catheters-locking solution in chronic hemodialysis].
Chazot G; Mehdi M; Lorriaux C; Deleaval P; Mayor B; Jean G; Chazot C; Lechevallier S; Moncel O; Vo-Van C; Hurot JM
Nephrol Ther; 2018 Feb; 14(1):42-46. PubMed ID: 29191576
[TBL] [Abstract][Full Text] [Related]
9. Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial.
Bonkain F; Van Hulle F; Janssens P; Catalano C; Allamani M; Stolear JC; Vandervelde D; Libertalis M; Treille S; Couttenye MM; Dhondt A; Van Biesen W; Fils JF; Tielemans C; Wissing KM
J Vasc Access; 2017 Sep; 18(5):436-442. PubMed ID: 28623638
[TBL] [Abstract][Full Text] [Related]
10. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.
Moore CL; Besarab A; Ajluni M; Soi V; Peterson EL; Johnson LE; Zervos MJ; Adams E; Yee J
Clin J Am Soc Nephrol; 2014 Jul; 9(7):1232-9. PubMed ID: 24970874
[TBL] [Abstract][Full Text] [Related]
11. An ethanol/sodium citrate locking solution compared to heparin to prevent hemodialysis catheter-related infections: a randomized pilot study.
Vercaigne LM; Allan DR; Armstrong SW; Zacharias JM; Miller LM
J Vasc Access; 2016; 17(1):55-62. PubMed ID: 26660041
[TBL] [Abstract][Full Text] [Related]
12. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
13. Substitution of citrate with tissue plasminogen activator (rt-PA) for catheter lock does not improve patency of tunnelled haemodialysis catheters in a randomised trial.
Richtrova P; Mares J; Kielberger L; Klaboch J; Eiselt J; Reischig T
BMC Nephrol; 2021 Jan; 22(1):41. PubMed ID: 33509107
[TBL] [Abstract][Full Text] [Related]
14. Risk factors associated with hemodialysis central venous catheter malfunction; a retrospective analysis of a randomized controlled trial.
Ward DR; Moist LM; MacRae JM; Scott-Douglas N; Zhang J; Tonelli M; Lok CE; Soroka SD; Hemmelgarn BR
Can J Kidney Health Dis; 2014; 1():15. PubMed ID: 25960883
[TBL] [Abstract][Full Text] [Related]
15. Tissue plasminogen activator vs heparin for locking central venous catheters between apheresis procedures.
Mathur G; Mott SL; Collins L; Schlueter AJ
J Clin Apher; 2019 Aug; 34(4):445-449. PubMed ID: 30829414
[TBL] [Abstract][Full Text] [Related]
16. Sodium citrate 4% locking solution for central venous dialysis catheters--an effective, more cost-efficient alternative to heparin.
Grudzinski L; Quinan P; Kwok S; Pierratos A
Nephrol Dial Transplant; 2007 Feb; 22(2):471-6. PubMed ID: 17065193
[TBL] [Abstract][Full Text] [Related]
17. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation.
Jiménez Hernández M; Soriano A; Filella X; Calvo M; Coll E; Rebled JM; Poch E; Graterol F; Compte MT; Maduell F; Fontsere N
J Vasc Access; 2021 May; 22(3):370-379. PubMed ID: 32691665
[TBL] [Abstract][Full Text] [Related]
18. Reevaluation of lock solutions for Central venous catheters in hemodialysis: a narrative review.
Wang Y; Sun X
Ren Fail; 2022 Dec; 44(1):1501-1518. PubMed ID: 36047812
[TBL] [Abstract][Full Text] [Related]
19. Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review.
Firwana BM; Hasan R; Ferwana M; Varon J; Stern A; Gidwani U
Avicenna J Med; 2011 Oct; 1(2):29-34. PubMed ID: 23210006
[TBL] [Abstract][Full Text] [Related]
20. Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial.
Bruyère R; Soudry-Faure A; Capellier G; Binquet C; Nadji A; Torner S; Blasco G; Yannaraki M; Barbar SD; Quenot JP
Trials; 2014 Nov; 15():449. PubMed ID: 25409678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
